Observational studyRenal failure2026
Urinary neutrophil gelatinase-associated lipocalin: a key biomarker for differentiating acute kidney injury and predicting short-term mortality in liver cirrhosis patients.
Observational study in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundurinary neutrophil gelatinase-associated lipocalin (uNGAL) has emerged as a promising biomarker in clinical settings for the differential diagnosis of acute kidney injury (AKI) in chronic liver disease (CLD). This prospective study aims to evaluate the efficiency of uNGAL in the differential diagnosis of AKI among patients with CLD and in predicting short-term mortality in this population.
methodsThis prospective observational study was conducted from September 2021 to March 2024 at Kasturba Medical College, Manipal, among patients with AKI and CLD. The study was initiated after obtaining institutional ethics committee approval. Demographic and clinical data, including urine samples for NGAL analysis, were collected. Patients were followed for 90 days to record clinical outcomes.
conclusionThis study shows that uNGAL distinguishes HRS from ATN and serves as a valuable predictor of 30-day and 90-day mortality. Additionally, higher levels of ALT, MELD-Na score, and uNGAL were identified as independent risk factors for mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.